Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression By Ogkologos - July 16, 2025 656 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATRACTIB study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Cancer in Lymph Nodes May Help Tumors Spread by Enlisting Immune... May 27, 2022 Immune Pathways Help Identify Patients with Cancer and HIV Most Likely... March 9, 2026 The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights... December 22, 2025 Imetelstat Shows Durable Transfusion Independence and Disease-Modifying Activity in Heavily Transfused... December 11, 2023 Load more HOT NEWS FDA Grants Traditional Approval to Selpercatinib for RET Fusion-positive Thyroid Cancer Judge Rules That 3-Year-Old Child With Leukemia Must Get Chemo Against... FDA Approves Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma
